Fong Y, Kemeny N, Paty P, Blumgart L H, Cohen A M
Colorectal Service, Department of Surgery, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Semin Surg Oncol. 1996 Jul-Aug;12(4):219-52. doi: 10.1002/(SICI)1098-2388(199607/08)12:4<219::AID-SSU3>3.0.CO;2-8.
Almost one-third of patients dying from colorectal cancer have tumor limited to the liver. Systemic chemotherapy is the appropriate palliative management of patients with metastases to the liver and other sites. For many patients with isolated hepatic metastases, systemic chemotherapy is also the most appropriate treatment. However, results with systemic chemotherapy indicate that one-third or less of patients will respond to such treatments, and long-term survival is rare. In this report we provide information concerning the natural history of colorectal hepatic metastases, followed by the expected benefits with systemic chemotherapy. This information provides background for the regional therapeutic strategies of surgical resection, cryosurgery, and hepatic artery chemotherapy. We discuss the selection factors appropriate for such treatments, morbidity and mortality, and the potential long-term benefits of such approaches. The last section focuses on surgical considerations in hepatic resection and hepatic artery chemotherapy.
死于结直肠癌的患者中,近三分之一的人肿瘤仅局限于肝脏。全身化疗是肝及其他部位转移患者合适的姑息治疗方法。对于许多孤立性肝转移患者,全身化疗也是最合适的治疗方法。然而,全身化疗的结果表明,只有三分之一或更少的患者会对这种治疗产生反应,长期存活的情况很少见。在本报告中,我们提供了有关结直肠癌肝转移自然病史的信息,随后介绍了全身化疗的预期益处。这些信息为手术切除、冷冻手术和肝动脉化疗等区域治疗策略提供了背景。我们讨论了适合此类治疗的选择因素、发病率和死亡率,以及这些方法潜在的长期益处。最后一部分重点讨论肝切除和肝动脉化疗中的手术注意事项。